RBI
NTLA icon

Raiffeisen Bank International’s Intellia Therapeutics NTLA Stock Holding History

Raiffeisen Bank International’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.8K Hold
2,000
– – ﹤0.01% 618
2026
Q1 		$25.6K Hold
2,000
– – ﹤0.01% 617
2025
Q4 		$15.2K Hold
2,000
– – ﹤0.01% 666
2025
Q3 		$34.5K Buy
+2,000
New +$24.6K ﹤0.01% 575

Other funds holding NTLA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Raiffeisen Bank International's NTLA Position: Q3 2025 in Review

Raiffeisen Bank International sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 2,000 shares — an estimated $24.6K sold.

Raiffeisen Bank International first reported a position in NTLA in Q4 2024 and held it in 3 quarters. The position peaked at $23.7K in Q4 2024. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Raiffeisen Bank International reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raiffeisen Bank International sold 2,000 Intellia Therapeutics shares in Q3 2025, an estimated $24.6K.
  • Raiffeisen Bank International first reported a position in Intellia Therapeutics in Q4 2024 and held it in 3 quarters.
  • Raiffeisen Bank International's Intellia Therapeutics position peaked at $23.7K in Q4 2024.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Raiffeisen Bank International's 13F filing for Q3 2025, filed 10 Nov 2025.